The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …

Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …